Observational study of cefepime therapeutic drug monitoring in continuous venovenous hemodialysis
Study context
- Population
- Critically ill adults in ICU receiving cefepime therapeutic drug monitoring (TDM) while on continuous venovenous hemodialysis (CVVHD)
- Participants
- 45 adults
- Outcome
- Achievement of pharmacokinetics (PK)/PK/pharmacodynamic (PD) target attainment
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Target attainment (PK/PD targets)
- Target attainment achieved, n (%) of 45 patients
- 28 (62.2 %)
- Cefepime total daily dose (TDD) >3 g associated with increased likelihood of target attainment
- p = 0.043
Observational data: associations, not effects.
Safety
Safety endpoint (supratherapeutic total cefepime levels)
- Safety endpoint occurred, n (%) of patients
- 15 (33.33 %)
- Higher BMI associated with elevated cefepime levels
- P = 0.049
- Cefepime TDD >3 g associated with elevated cefepime levels
- P = 0.029
- Lower CVVHD therapy rate associated with elevated cefepime levels
- P = 0.033
Potential cefepime-induced neurotoxicity (CIN; Naranjo scale)
- Potential CIN occurred, n (%) of patients
- 13 (28.8 %)
- Higher total cefepime trough levels associated with increased likelihood of CIN
- P = 0.033
Original publication
Observational study of cefepime therapeutic drug monitoring in continuous venovenous hemodialysis. J Crit Care. Published 9 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →